Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M291,304Revenue $M71,312Net Margin (%)23.3Z-Score5.6
Enterprise Value $M273,566EPS $4.8Operating Margin %28.1F-Score7
P/E(ttm))17.3Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book3.810-y EBITDA Growth Rate %3.5Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-0.9Current Ratio2.6Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %23.6ROA % (ttm)13.1Higher Current Ratio y-yY
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)23.1Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M2,799ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 104.070%New holding, 14319 sh.14,319
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 104.070%Add 27.77%84,193
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 104.070%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 104.070%Reduce -99.8%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 104.070%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 104.070%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 104.070%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 104.070%Reduce -3.7%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 104.070%Sold Out0
JNJJohn Rogers 2014-06-30 Add0.2%$96.54 - $105.76
($101.02)
$ 104.073%Add 42.46%522,727
JNJRichard Pzena 2014-06-30 Add0.17%$96.54 - $105.76
($101.02)
$ 104.073%Add 33.12%1,155,666
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -13.16%3,300,000
JNJRobert Olstein 2014-06-30 Reduce-0.31%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -20.91%87,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -5.5%9,045,902
JNJTweedy Browne 2014-06-30 Reduce-0.17%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -1.71%4,196,224
JNJRay Dalio 2014-06-30 Reduce-0.16%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -74.94%65,893
JNJGeorge Soros 2014-06-30 Reduce-0.05%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -51.22%50,000
JNJJoel Greenblatt 2014-06-30 Sold Out -0.01%$96.54 - $105.76
($101.02)
$ 104.073%Sold Out0
JNJJohn Hussman 2014-06-30 Reduce-0.01%$96.54 - $105.76
($101.02)
$ 104.073%Reduce -50%1,325
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Joel Greenblatt 2014-09-3014,31900.02New Buy
JNJ Ray Dalio 2014-09-3084,19300.07+27.77%
JNJ Dodge & Cox 2014-09-3047,09500+21.93%
JNJ John Rogers 2014-09-30536,6160.020.74+2.66%
JNJ Richard Pzena 2014-09-301,184,4160.040.69+2.49%
JNJ Jean-Marie Eveillard 2014-09-301,651,6220.060.44+1.73%
JNJ Richard Snow 2014-09-303,27000.01+0.77%
JNJ Ruane Cunniff 2014-09-3076,25900.04+0.32%
JNJ Richard Perry 2014-09-30342,2770.011.3
JNJ Warren Buffett 2014-09-30327,1000.010.03
JNJ John Hussman 2014-09-301,32500.01
JNJ Brian Rogers 2014-09-304,633,0000.171.8
JNJ Tom Gayner 2014-09-30574,2000.021.7
JNJ Michael Price 2014-09-3035,00000.47
JNJ Ken Fisher 2014-09-3010,446,1560.372.4-0.02%
JNJ PRIMECAP Management 2014-09-3012,217,8130.441.4-0.2%
JNJ Tweedy Browne 2014-09-304,163,9340.1510.2-0.77%
JNJ Mario Gabelli 2014-09-30366,3660.010.21-1.83%
JNJ Prem Watsa 2014-09-3082,85000.6-2.18%
JNJ Yacktman Fund 2014-09-303,900,0000.143.6-3.7%
JNJ Donald Yacktman 2014-09-308,651,2580.313.8-4.36%
JNJ Robert Olstein 2014-09-3083,00001.2-4.6%
JNJ Yacktman Focused Fund 2014-09-303,100,0000.113.5-6.06%
JNJ James Barrow 2014-09-3015,350,6500.552.2-10.05%
JNJ HOTCHKIS & WILEY 2014-09-302,86200-99.8%
JNJ George Soros 2014-09-30000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JOHNSON & JOHNSON10% Owner 2014-12-12Sell5,000$7.511268.31view
JOHNSON & JOHNSON10% Owner 2014-12-10Sell8,300$7.721231.09view
JOHNSON & JOHNSON10% Owner 2014-12-05Sell15,900$7.761224.23view
JOHNSON & JOHNSON10% Owner 2014-12-01Sell1,200$7.541262.86view
JOHNSON & JOHNSON10% Owner 2014-11-26Sell2,000$7.751225.94view
JOHNSON & JOHNSON10% Owner 2014-11-24Sell9,500$8.141162.41view
JOHNSON & JOHNSON10% Owner 2014-11-12Buy40,000$18470.89view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-5.33view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-4.35view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-1.31view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Boston Scientific Lost the First Place in Innovation Dec 11 2014 
    Dividends vs. Stock Buybacks Dec 09 2014 
    Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
    test_app_3 Nov 28 2014 
    test_app_3 Nov 28 2014 
    test_app_2 Nov 28 2014 
    test_app Nov 28 2014 
    U.S. Stocks Attractive As Euro-Area Economy Slides Nov 26 2014 
    Consolidated Edison Has Increased Dividends for 40 Years Nov 25 2014 
    Buy & Hold – Boring and Outdated Way to Invest? Nov 24 2014 


    More From Other Websites
    Is This The Future Of Late-Stage Drug Development? Dec 15 2014
    Sucampo Appoints John H. Johnson to Board of Directors Dec 15 2014
    J&J Tuberculosis Drug Poised for Expanded Reach Dec 11 2014
    Johnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to... Dec 11 2014
    APAC Joint Replacement Market to Reach $6.4 Billion by 2020 Dec 10 2014
    Covidien Loses $176M Award in Patent Case Against JNJ Unit Dec 09 2014
    Stop Waiting for Johnson & Johnson To Break Up or Down Dec 09 2014
    Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
    Ebola, Ethics, And The New Normal Of Scary Germs Dec 04 2014
    Johnson & Johnson Dec 03 2014
    Alzheimer's drug shows promise Dec 03 2014
    Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Dec 02 2014
    Biogen Alzheimer's Drug Succeeding In Early Tests Dec 02 2014
    Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million... Dec 01 2014
    Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 Nov 27 2014
    Spanx for Your Face Nov 26 2014
    Health Care ETFs Healthy on a Global Basis, Too Nov 26 2014
    Apple eyes holiday sales Nov 26 2014
    Apple breaks $700 billion Nov 25 2014
    It was another slow, low volume, lackluster trading session Nov 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK